EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Price, Timothy ^{[1
]}

Chawla, Sant ^{[2
]}

Falchook, Gerald ^{[3
]}

Prenen, Hans ^{[4
]}

Lugowska, Iwona ^{[5
]}

Subbiah, Vivek ^{[6
]}

Monzon, Jose ^{[7
]}

Ozawa, Yuichi ^{[8
]}

Arkenau, Tobias ^{[9
]}

Lima, Caio Rocha ^{[10
]}

Kuboki, Yasutoshi ^{[11
]}

Nishina, Tomohiro ^{[12
]}

Hui, Mun ^{[13
]}

Rasmussen, Erik ^{[14
]}

Wong, Hansen ^{[14
]}

Najmi, Saltanat ^{[14
]}

Sadraei, Nooshin ^{[14
]}

机构：

[1] Univ Adelaide, Queen Elizabeth Hosp Campus, CALHN, Woodville, SA, Australia

[2] Sarcoma Oncol Ctr, Santa Monica, CA USA

[3] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[4] Univ Hosp Antwerp, Antwerp, Belgium

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Texas MD Anderson Canc, Houston, TX USA

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Wakayama Med Univ Hosp, Wakayama, Japan

[9] Sarah Cannon Res Inst UK, London, England

[10] Wake Forest Baptist Hlth, Miami, FL USA

[11] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[13] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[14] Amgen Inc, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

403

引用

页码：A245 / A245

页数：1

共 50 条

[1] Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies
Seitz, L. C.
Rieger, A.
Berry, W.
Ashok, D.
Direnzo, D.
Jin, L.
Lee, S. J.
Park, A.
Piovesan, D.
Tan, J. B. L.
Walters, M. J.
Karakunnel, J.
ANNALS OF ONCOLOGY, 2018, 29
[2] Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma
Xu, N.
Han, B.
Jiao, S.
Hu, C.
Mislang, A.
Coward, J.
Cooper, A.
Underhill, C.
Xia, Y.
Xia, D.
Jin, X.
Wang, Z. M.
Li, B.
ANNALS OF ONCOLOGY, 2020, 31 : S1428 - S1429
[3] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
Desai, Jayesh
Markman, Ben
Sandhu, Shahneen Kaur
Gan, Hui Kong
Friedlander, Michael
Tran, Ben
Meniawy, Tarek
Boolell, Vishal
Colyer, Duncan
Norris, Christie
Ameratunga, Malaka
Yang, Jason
Li, Kang
Wang, Lai
Luo, Lusong
Qin, Zhen
Millward, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
Xu, Jian-Ming
Jia, Ru
Wang, Yan
Liu, Rongrui
Zhao, Chuanhua
Zhou, Hui
Xu, Linxinyu
Kong, Xuan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] A phase I trial of BI 754091, a programmed death receptor 1 (PD-1) inhibitor, in patients with advanced solid tumors
Johnson, Melissa
Patel, Manish
Siu, Lillian
Aljumaily, Raid
Kozloff, Mark
Vaishampayan, Ulka
Elgadi, Mabrouk
Ge, Miaomiao
Duffy, Christine
Graeser, Ralph
Buschke, Susanne
Khedkar, Sheetal
Jones, Suzanne F.
Burrisiii, Howard A.
ANNALS OF ONCOLOGY, 2018, 29
[6] NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]; BMS-936558) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: CLINICAL ACTIVITY, SAFETY, AND MOLECULAR MARKERS
Feltquate, D. M.
ANNALS OF ONCOLOGY, 2013, 24 : 7 - 7
[7] Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study
Le Cesne, A.
Marec-Berard, P.
Blay, J. -Y.
Gaspar, N.
Bertucci, F.
Penel, N.
Bompas, E.
Cousin, S.
Toulmonde, M.
Bessede, A.
Fridman, W. H.
Sautes-Fridman, C.
Kind, M.
Le Loarer, F.
Pulido, M.
Italiano, A.
EUROPEAN JOURNAL OF CANCER, 2019, 119 : 151 - 157
[8] Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
Rajan, Arun
Kim, Chul
Heery, Christopher R.
Guha, Udayan
Gulley, James L.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2219 - 2231
[9] Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer
Qiu, Hao
Zheng, Liang
Tang, Weifeng
Yin, Pengfei
Cheng, Feng
Wang, Lixin
CLINICAL BIOCHEMISTRY, 2014, 47 (7-8) : 612 - 617
[10] A phase 1 trial of JS']JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.
Yang, Sheng
Yang, Jianliang
Han, Ying
Qin, Yan
Han, Xiaohong
Dong, Lihou
Feng, Hui
Song, Haifeng
Sun, Yan
Shi, Yuankai
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →